HK1093869A1 - Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes - Google Patents

Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes

Info

Publication number
HK1093869A1
HK1093869A1 HK07100699.7A HK07100699A HK1093869A1 HK 1093869 A1 HK1093869 A1 HK 1093869A1 HK 07100699 A HK07100699 A HK 07100699A HK 1093869 A1 HK1093869 A1 HK 1093869A1
Authority
HK
Hong Kong
Prior art keywords
prevention
treatment
methods
pharmaceutical formulations
acute coronary
Prior art date
Application number
HK07100699.7A
Other languages
English (en)
Inventor
Charles L Bisgaier
Wendi V Rodrigueza
Narendra D Lalwani
Daniel Hartman
Jan Johansson
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of HK1093869A1 publication Critical patent/HK1093869A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07100699.7A 2003-10-20 2007-01-19 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes HK1093869A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14
PCT/US2004/034800 WO2005041866A2 (en) 2003-10-20 2004-10-19 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes

Publications (1)

Publication Number Publication Date
HK1093869A1 true HK1093869A1 (en) 2007-03-16

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100699.7A HK1093869A1 (en) 2003-10-20 2007-01-19 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes

Country Status (24)

Country Link
US (2) US7435717B2 (xx)
EP (1) EP1677597B1 (xx)
JP (1) JP2007509157A (xx)
KR (3) KR20100101710A (xx)
AR (1) AR046126A1 (xx)
AU (2) AU2004284932A1 (xx)
CA (1) CA2542726C (xx)
CO (1) CO5690611A2 (xx)
CR (1) CR8352A (xx)
EA (1) EA010134B1 (xx)
EC (1) ECSP066516A (xx)
ES (1) ES2449719T3 (xx)
GE (1) GEP20094601B (xx)
HK (1) HK1093869A1 (xx)
IL (1) IL174301A (xx)
MA (1) MA28102A1 (xx)
MX (1) MXPA06004362A (xx)
NO (1) NO339456B1 (xx)
NZ (1) NZ545939A (xx)
OA (1) OA13272A (xx)
PA (1) PA8615301A1 (xx)
PE (1) PE20050438A1 (xx)
RS (1) RS20060273A (xx)
WO (1) WO2005041866A2 (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
JP2005504085A (ja) * 2001-09-28 2005-02-10 エスペリオン セラピューティクス,インコーポレイテッド 薬剤の局所投与による再狭窄の予防および治療
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ メディカル センター アポリポタンパク質a−iおよびアポリポタンパク質a−imilanoをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
KR20080017489A (ko) * 2005-07-22 2008-02-26 더 프록터 앤드 갬블 캄파니 약물 유발성 부정맥 발생률 감소용 조성물
EP1986735A4 (en) * 2006-02-06 2011-06-29 Northwind Ventures SYSTEMS AND METHODS FOR VOLUME REDUCTION
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
US20080009487A1 (en) * 2006-03-03 2008-01-10 Andrew Sternlicht Treatment of athersclerotic disease
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
CA2752899A1 (en) * 2009-02-18 2010-08-26 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
EP2401587A2 (en) 2009-02-27 2012-01-04 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US8790242B2 (en) 2009-10-26 2014-07-29 Cardiokinetix, Inc. Ventricular volume reduction
PL3178481T3 (pl) 2010-06-30 2019-07-31 Csl Limited Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji
BR112013004395A2 (pt) 2010-08-30 2019-09-24 Hoffmann La Roche tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização
EP2611417A2 (en) 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Method for producing a tetranectin-apolipoprotein a-1 particle, the lipid particle obtained therewith and its use
RU2013111678A (ru) 2010-08-30 2014-10-10 Ф. Хоффманн-Ля Рош Аг Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
CN103443123B (zh) * 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
ES2663635T3 (es) * 2011-04-27 2018-04-16 Ionis Pharmaceuticals, Inc. Modulación de la expresión de apolipoproteína CIII (APOCIII)
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
JP6207507B2 (ja) 2011-08-25 2017-10-04 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 短縮されたテトラネクチン−アポリポプロテインa−i融合タンパク質、それを含む脂質粒子、及びその使用
MX2014006589A (es) * 2011-12-21 2014-10-17 Csl Ltd Régimen de dosificación para formulaciones de apolipoproteína.
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP3378507B1 (en) * 2013-10-31 2020-06-10 Novo Nordisk A/S Injection device with a needle cannula
WO2016048802A1 (en) 2014-09-28 2016-03-31 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
AU2016311047B2 (en) * 2015-08-25 2020-12-10 Novo Nordisk A/S A medical injection device with a cleaning chamber
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
JP2005504085A (ja) * 2001-09-28 2005-02-10 エスペリオン セラピューティクス,インコーポレイテッド 薬剤の局所投与による再狭窄の予防および治療
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia

Also Published As

Publication number Publication date
EP1677597A4 (en) 2011-08-24
EA010134B1 (ru) 2008-06-30
GEP20094601B (en) 2009-02-10
RS20060273A (sr) 2008-09-29
EP1677597B1 (en) 2014-01-08
ES2449719T3 (es) 2014-03-20
PA8615301A1 (es) 2005-09-28
ECSP066516A (es) 2006-11-24
NZ545939A (en) 2008-08-29
KR20100101710A (ko) 2010-09-17
NO20062110L (no) 2006-07-18
US20080293633A1 (en) 2008-11-27
CR8352A (es) 2007-03-02
EP1677597A2 (en) 2006-07-12
PE20050438A1 (es) 2005-06-14
CA2542726C (en) 2012-05-15
AU2011202014A1 (en) 2011-05-26
US20050142180A1 (en) 2005-06-30
IL174301A0 (en) 2006-08-01
OA13272A (en) 2007-01-31
EA200600548A1 (ru) 2006-10-27
IL174301A (en) 2013-09-30
AU2011202014B2 (en) 2012-06-14
CO5690611A2 (es) 2006-10-31
AU2004284932A1 (en) 2005-05-12
CA2542726A1 (en) 2005-05-12
WO2005041866A3 (en) 2006-05-18
JP2007509157A (ja) 2007-04-12
NO339456B1 (no) 2016-12-12
WO2005041866A2 (en) 2005-05-12
MA28102A1 (fr) 2006-08-01
MXPA06004362A (es) 2006-09-04
US7435717B2 (en) 2008-10-14
KR20070110561A (ko) 2007-11-19
KR20060080227A (ko) 2006-07-07
AR046126A1 (es) 2005-11-23

Similar Documents

Publication Publication Date Title
IL174301A0 (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
AP2006003596A0 (en) A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases.
IL241211B (en) History of itansinoid and pharmaceutical preparations containing them
PL400027A1 (pl) Wieloelementowa farmaceutyczna postac dawkowania i sposób jej wytwarzania
IL166232A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL177807A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL178414A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
AP2005003382A0 (en) Liquid pharmaceutical formulations of palonosetron.
IL175499A (en) Pneumococcal Niraminadase non-toxic and pharmaceutical preparations containing it
ZA200410211B (en) Quinuclidine derivatives and pharmaceutical compositions containing the same.
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
IL173628A0 (en) Aminopyridine derivatives and pharmaceutical compositions containing the same
IL180303A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
AP2005003362A0 (en) Formulation and methods for the treatment of thrombocythemia.
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171019